DRUG · Mapped RxNorm record
Roflumilast
Normalized identity: roflumilastView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
NCT00297115
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedEffect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
RoflumilastDRUG · verified · RxNorm: roflumilast
PlaceboDRUG
Sponsors & collaborators
AstraZenecalead sponsor
Mapped research locations
BerlinGermany8ToledoOhio, United States3HoustonTexas, United States2PhiladelphiaPennsylvania, United States2St LouisMissouri, United States2MiamiFlorida, United States2San AntonioTexas, United States2MadridSpain2BirminghamAlabama, United States2San DiegoCalifornia, United States2MontrealQuebec, Canada2IndianapolisIndiana, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00297115 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.